RxDoctor Payments Data

Andrew Fischer, MD

Dermatopathology · Houston, TXNPI 1528453057

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.2% of the total across 576 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations.

$11,375in general payments, 2019–2025

Across 576 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Novartis$950
  • Lilly USA, LLC$878
  • Revance Therapeutics, Inc.$839
  • plus $5K from 25 others

What the payments were for

  • Food & beverage$11,16598%
  • Education$2102%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,375 in reported general payments places this provider in the 85th percentile of 54 dermatopathology providers in Texas.

See all dermatopathology providers in Texas

Medicare billing

Part B allowed, 2024
$223,817
Medicare patients
1,037
Services billed
2,887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa11$254,729
Dupixent PenDupilumab13$50,214
Clobetasol Propionate82$3,580
Tacrolimus17$2,280
Fluorouracil22$1,554
Ketoconazole92$1,327
Triamcinolone Acetonide82$1,015
Clindamycin Phosphate15$563
Fluocinonide11$534
Dutasteride13$482
Doxycycline Monohydrate16$459
Fluconazole32$403
Doxycycline Hyclate23$386
Minoxidil27$356
Hydrocortisone37$206

Paid to pharmacies, not to this prescriber.

Other dermatopathology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →